Received Oct 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 9JT4S | — |
the HCP mentioned that it was not a 4-month period, it was a 5-month period; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 59-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 9JT4S) for prophylaxis. Previously administered products included Boostrix (received 1st dose of boostrix on 2 APR 2025, batch number XN575). On 04-SEP-2025, the patient received the 2nd dose of Boostrix. On 04-SEP-2025, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: the HCP mentioned that it was not a 4-month period, it was a 5-month period). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-SEP-2025 During the call, the reporter mentioned that it was not a 4-month period, it was a 5-month period. The vaccine administration facility was the same as primary reporter.